!!Francis Megraud - Selected Publications
\\
Mégraud F, Bonnet F, Garnier M, Lamouliatte H. Characterization of "Campylobacter pyloridis" by culture, enzymatic profile, and protein content. J Clin Microbiol. 1985;22(6):1007-10.\\
\\
 Mégraud F, Brassens-Rabbé MP, Denis F, Belbouri A, Hoa DQ. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol. 1989;27(8):1870-3.\\
\\
 Monteiro L, Bonnemaison D, Vekris A, Petry KG, Bonnet J, Vidal R, Cabrita J, Mégraud F. Complex polysaccharides as PCR inhibitors in feces: Helicobacter pylori model. J Clin Microbiol. 1997;35(4):995-8\\
\\
 Marais A, Mendz GL, Hazell SL, Mégraud F. Metabolism and genetics of Helicobacter pylori: the genome era. Microbiol Mol Biol Rev. 1999;63(3):642-74.\\
\\
 Avenaud P1, Marais A, Monteiro L, Le Bail B, Bioulac Sage P, Balabaud C, Mégraud F. Detection of Helicobacter species in the liver of patients with and without primary liver carcinoma. Cancer. 2000;89(7):1431-9.\\
\\
 Broutet N, Tchamgoué S, Pereira E, Lamouliatte H, Salamon R, Mégraud F. Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther. 2003;17(1):99-109.\\
\\
 Oleastro M1, Ménard A, Santos A, Lamouliatte H, Monteiro L, Barthélémy P, Mégraud F. Real-time PCR assay for rapid and accurate detection of point mutations conferring resistance to clarithromycin in Helicobacter pylori. J Clin Microbiol. 2003 ;41(1):397-402.\\
\\
 Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F; Pylera Study Group. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet. 2011;377:905-13.\\
\\
 Mégraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y; Study Group participants. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34-42.\\
\\
 Mégraud F, Bruyndonckx R, Coenen S, Wittkop L, Huang TD, Hoebeke M, Bénéjat L, Lehours P, Goossens H, Glupczynski Y, European Helicobacter pylori Antimicrobial Susceptibility Testing Working Group. Helicobacter pylori resistance to antibiotics in Europe in 2018 and its relationship to antibiotic consumption in the community. Gut. 2021 Oct;70(10):1815-1822.